All In Biotech

Drug Trial Radar · NCT00000922

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

A Randomized, Open-Label Study of the Long-Term Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART) Strategies in HAART-Niave, HIV-Infected Persons

Last checked: Nov 19, 2026Latest source record: Apr 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,710 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,710

Actual

Start

Not stated

Primary completion

Jan 2003

Study completion Jun 2006

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether it is better to start an anti-HIV regimen containing a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a PI in combination with an NNRTI. This study will also examine which treatment regimen is best as a first treatment for HIV infection.

Conditions

  • HIV Infections

Interventions

  • Indinavir sulfateDrug

  • Abacavir sulfateDrug

  • Nelfinavir mesylateDrug

  • EfavirenzDrug

  • NevirapineDrug

  • LamivudineDrug

  • StavudineDrug

  • DidanosineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in CD4 count from baseline to the average of all readings obtained at the regular follow-up visits beginning at Month 32
  2. time to disease progression, death, or CD4 count less than 200 cells/mm3 at the 4 Month visit for those patients with a baseline CD4 cell count of more than or equal to 200 cells/mm3

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Community Consortium / UCSF

    San Francisco, California

  • Denver CPCRA / Denver Public Hlth

    Denver, Colorado

  • Yale Univ School of Medicine / AIDS Program

    New Haven, Connecticut

  • Washington Reg AIDS Prog / Dept of Infect Dis

    Washington D.C., District of Columbia

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • AIDS Research Alliance - Chicago

    Chicago, Illinois

  • Louisiana Comm AIDS Rsch Prog / Tulane Univ Med

    New Orleans, Louisiana

  • Wayne State Univ - WSU/DMC / Univ Hlth Ctr

    Detroit, Michigan

  • Henry Ford Hosp

    Detroit, Michigan

  • Southern New Jersey AIDS Cln Trials / Dept of Med

    Camden, New Jersey

  • North Jersey Community Research Initiative

    Newark, New Jersey

  • Partners in Research / New Mexico

    Albuquerque, New Mexico

  • Harlem AIDS Treatment Grp / Harlem Hosp Ctr

    New York, New York

  • The Research and Education Group

    Portland, Oregon

  • Philadelphia FIGHT

    Philadelphia, Pennsylvania

  • Univ TX Health Science Ctr

    Houston, Texas

  • Richmond AIDS Consortium / Div of Infect Diseases

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.